A334970 Stock Overview
Specializes in the development and production of biologic agents and biosimilars.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Prestige Biologics Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩4,800.00 |
52 Week High | ₩5,550.00 |
52 Week Low | ₩3,850.00 |
Beta | 1.15 |
11 Month Change | 14.42% |
3 Month Change | 16.79% |
1 Year Change | 10.85% |
33 Year Change | -65.71% |
5 Year Change | n/a |
Change since IPO | -66.43% |
Recent News & Updates
Recent updates
Shareholder Returns
A334970 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 12.9% | 0.8% | -2.4% |
1Y | 10.9% | 26.2% | 5.4% |
Return vs Industry: A334970 underperformed the KR Biotechs industry which returned 29.4% over the past year.
Return vs Market: A334970 exceeded the KR Market which returned 6% over the past year.
Price Volatility
A334970 volatility | |
---|---|
A334970 Average Weekly Movement | 4.4% |
Biotechs Industry Average Movement | 8.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A334970 has not had significant price volatility in the past 3 months.
Volatility Over Time: A334970's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | n/a | pbpharma.co.kr |
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd.
Prestige Biologics Co., Ltd. Fundamentals Summary
A334970 fundamental statistics | |
---|---|
Market cap | ₩295.21b |
Earnings (TTM) | -₩39.44b |
Revenue (TTM) | ₩1.75b |
169.1x
P/S Ratio-7.5x
P/E RatioIs A334970 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A334970 income statement (TTM) | |
---|---|
Revenue | ₩1.75b |
Cost of Revenue | ₩1.25b |
Gross Profit | ₩493.75m |
Other Expenses | ₩39.94b |
Earnings | -₩39.44b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -641.31 |
Gross Margin | 28.28% |
Net Profit Margin | -2,259.19% |
Debt/Equity Ratio | 160.3% |
How did A334970 perform over the long term?
See historical performance and comparison